ASM Microbe 2016 (June 16–20, 2016, Boston, MA)
|Publication Type||Conference paper|
As a result of treatment of “classic” bacterial infections in cystic fibrosis (CF), there are now increasing problems with innately resistant new airway pathogens such as S.maltophilia, A.xylosoxidans, M.abscessus. These bacteria are associated with higher morbidity among CF patients and display high resistance to antimicrobials. The aim of the present study was to compare selected antimicrobials against these planktonic and sessile pathogens.
We used clinical isolates of S.maltophiliaand A.xylosoxidans from cystic fibrosis patients and a clinical isolate of M.abscessus. Two antimicrobial agents were tested: novel broad spectrum antimicrobial Mul-1867 and amikacin as representative aminoglycosides that are commonly used to treat CF patients. The anti-biofilm activity against 48-h-old S.maltophiliaand A.xylosoxidans biofilms was evaluated as minimum biofilm eliminating concentration that completely eradicated mature biofilms (MBEC100). Biofilms were exposed for 24 h containing antibacterial at 1 – 128× the MIC. All assays were repeated in triplicate.
Mul-1867 exhibited a high level of antimicrobial activity against all strains with the MIC values 0.125 mg/L against S.maltophilia, 0.25 mg/L against A.xylosoxidans and 2.0 mg/L against M.abscessus. Amikacin was less active than Mul-1867; the MIC for S.maltophilia was 128 mg/L, for A.xylosoxidans was 25 mg/L, and for M.abscessus 8.0 mg/L. Mul-1867 showed MBEC100 values of 2× and 4× the MIC, respectively, against S.maltophilia and A.xylosoxidans. Amikacin displayed lower antibiofilm activity against S.maltophilia and A.xylosoxidans with MBEC100 values of 128× and 64× the MIC, respectively.
In the current study, we found that a novel drug candidate, Mul-1867, exhibits a high level of antimicrobial activity against S.maltophilia, A.xylosoxidans and M.abscessus. We revealed that Mul-1867 was more active than amikacin against selected clinical isolates, displayed lower MICs and possessed low MBEC100/MIC. The efficacy of Mul-1867 raises the possibility that it may serve as a locally acting antimicobial compound in CF patients.
|Year of Publication||2016|
|Journal||ASM Microbe 2016 (June 16–20, 2016, Boston, MA)|